Form 4: Genmab Boosts Merus Stake Post-Tender Offer

Genmab A/S, through its subsidiary, increased its beneficial ownership in Merus N.V. by acquiring additional common shares at $97.00 per share following a tender offer.

Summary

• Genmab A/S, through its wholly-owned subsidiary Genmab Holding II B.V. (Purchaser), acquired additional common shares of Merus N.V.
• The acquisitions occurred on December 16, 2025 (120,752 shares) and December 17, 2025 (150,795 shares) at a price of $97.00 per share.
• These purchases were part of a subsequent offering period following a tender offer initiated by Purchaser for all outstanding Merus common shares.
• The initial tender offer, based on a Transaction Agreement dated September 29, 2025, resulted in Purchaser accepting 71,463,077 common shares (approximately 94.2% of outstanding shares) on December 12, 2025, also at $97.00 per share.
• Following these transactions, Genmab A/S indirectly beneficially owns 71,734,624 common shares of Merus N.V.

Sentiment

Score: 8

Explanation: The filing indicates the successful near-completion of a strategic acquisition by Genmab A/S, demonstrating strong execution of its corporate strategy and significant investment in Merus N.V. This is a positive development for Genmab, consolidating its control over Merus's assets.

Positives

• Genmab A/S has significantly increased its stake in Merus N.V., indicating strong confidence in the company.
• The acquisition of 94.2% of Merus's outstanding shares suggests a near-complete takeover, potentially leading to full integration and strategic synergies.
• The tender offer price of $97.00 per share provides a clear valuation for Merus shareholders who tendered their shares.

Future Outlook

The filing is a Form 4, reporting past transactions. It does not contain explicit forward-looking statements or guidance beyond the completion of the tender offer and subsequent acquisitions. The implication is a full integration of Merus into Genmab.

Management Comments

• On September 29, 2025, Genmab A/S ("Parent"), Genmab Holding II B.V., a wholly owned subsidiary of Parent ("Purchaser"), and the Issuer entered into a transaction agreement (the "Transaction Agreement").
• Pursuant to the terms of the Transaction Agreement, Purchaser commenced a tender offer for all the issued and outstanding common shares... of the Issuer.
• On December 12, 2025, following the expiration of the initial offering period of the Offer... Purchaser accepted 71,463,077 Common Shares... representing approximately 94.2% of the Issuer's outstanding Common Shares, in exchange for a cash payment equal to $97.00 per Common Share.
• On December 12, 2025, Purchaser commenced a subsequent offering period during which Purchaser acquired an additional 120,752 Common Shares on December 16, 2025 and an additional 150,795 Common Shares on December 17, 2025.
• Parent, as the parent entity of Purchaser, beneficially owns the Common Shares held directly by Purchaser.

Industry Context

This transaction represents a significant consolidation in the biotechnology or pharmaceutical sector, where larger companies often acquire smaller, innovative firms to expand their pipeline or technology platforms. Merus N.V. is likely a company with valuable assets (e.g., drug candidates, intellectual property) that Genmab A/S seeks to integrate into its operations. The acquisition of over 94% of shares indicates a strategic move towards full control.

Comparison to Industry Standards

• The acquisition of a significant majority stake (94.2%) through a tender offer is a common strategy for corporate takeovers in the biotechnology and pharmaceutical industries, similar to transactions seen with companies like Gilead Sciences acquiring Kite Pharma or Bristol Myers Squibb acquiring Celgene.
• The cash payment of $97.00 per share suggests a premium or fair valuation for Merus N.V. at the time of the offer, consistent with typical acquisition multiples in the sector for companies with promising drug pipelines or technologies.
• The subsequent offering period to acquire additional shares is a standard procedure to consolidate ownership further after the initial tender offer, aiming for a full acquisition or squeeze-out.

Related Party Transactions

• Genmab A/S, as a 10% owner and director of Merus N.V., is involved in the acquisition of Merus shares through its wholly-owned subsidiary, Genmab Holding II B.V. This constitutes a transaction where the reporting person has a pre-existing relationship with the issuer.

Stakeholder Impact

• Shareholders (Merus N.V.): Those who tendered their shares received $97.00 per share in cash. Remaining shareholders may face reduced liquidity and potential future compulsory acquisition (squeeze-out) by Genmab.
• Shareholders (Genmab A/S): The acquisition represents a significant strategic investment, potentially enhancing Genmab's pipeline, market position, and long-term value, but also involves a substantial cash outlay.
• Employees (Merus N.V.): Likely to experience integration into Genmab's corporate structure, which could involve changes in roles, reporting lines, or corporate culture.
• Customers/Partners (Merus N.V.): May see continuity or changes in product development and commercialization strategies under Genmab's ownership.

Next Steps

• Potential full integration of Merus N.V. into Genmab A/S operations.
• Possible squeeze-out of remaining minority shareholders of Merus N.V.
• Further regulatory filings related to the change in control and ownership.

Key Dates

Recommendation

This Form 4 filing details the completion of a tender offer and subsequent share acquisitions by Genmab A/S for Merus N.V. The transaction is largely complete, with Genmab now owning over 94% of Merus. For Merus shareholders, the opportunity to tender at $97.00 per share has largely passed, and remaining shares face potential illiquidity or a future squeeze-out. For Genmab shareholders, this confirms the execution of a strategic acquisition, which is generally positive for long-term growth but the immediate impact of this specific filing (reporting past transactions) is neutral as the market would have already priced in the tender offer. Therefore, a "hold" recommendation is appropriate for both, as the primary event has occurred, and further significant price movement based solely on this Form 4 is unlikely. Investors should now focus on the integration process and future performance of the combined entity.

Keywords

Genmab A/S, Merus N.V., MRUS, Tender Offer, Acquisition, Common Shares, Beneficial Ownership, SEC Form 4, Biotechnology, Pharmaceuticals